Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 341, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.jneuroim.2020.577184
Keywords
Paraneoplastic syndrome; Immune checkpoint inhibitor; Anti-PD-1 inhibitor; Nivolumab, anti-Hu antibody; Neurologic immune related adverse events
Categories
Ask authors/readers for more resources
We present an illustrative case of a 62-year-old woman with small cell lung cancer who developed progressive worsening of pre-existing anti-Hu antibody associated sensory neuronopathy after treatment with programmed cell death-1 (PD-1) inhibitor, nivolumab. We review the literature and identify 6 reported cases to understand the clinical outcomes of patients with anti-Hu paraneoplastic neurologic syndrome (PNS) treated with anti-PD-1 treatment. The PNS clinical spectrum comprised of encephalitis, a combination of sensory neuronopathy and anti-NMDAR encephalitis, isolated sensory neuronopathy, and encephalomyelitis. Immune checkpoint inhibitor have the potential to worsen pre-existing anti-Hu PNS and may promote the development of anti-Hu PNS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available